Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06895343 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

A Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

Active
Registry status
Phase 1
Development phase
100
Enrollment target
2
Study locations

NCT06895343: Active Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

NCT06895343 is a Phase 1 study of Healthy Volunteer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 100 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06895343, a Phase 1 study of Healthy Volunteer, is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.

Primary Outcome

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG ABBV-701

Study Locations (2)

California

  • CenExel ACT- Anaheim Clinical Trials /ID# 278431 - Anaheim

Illinois

  • Acpru /Id# 273354 - Grayslake

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-03
Est. Completion 2026-11
Phase Phase 1
AbbVie

526 total trials

What the registry record for NCT06895343 still lists

NCT06895343 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (50% lower).

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06895343 reports a single indexed study location in California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06895343 about?

NCT06895343 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants". The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.

What is the current status of trial NCT06895343?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-04-03. Estimated completion is 2026-11.

What conditions does trial NCT06895343 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT06895343?

The interventions under investigation include: Placebo (DRUG), ABBV-701 (DRUG).

Who is sponsoring clinical trial NCT06895343?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06895343 being conducted?

This trial has 2 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06895343's enrollment target sits among peer trials

100 31st of 112 higher than 80 of 112 other Healthy Volunteer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06895343, the US trial registry maintained by the National Library of Medicine. NCT06895343 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.